Brensocatib

自由鼻肺站导读 对于慢阻肺患者来说，新药的出现就意味着更多治疗选择。今天就给大家整理一份2026年慢阻肺新药干货，不管是已获批能直接用的，还是正在研发的，方便大家快速获取关键信息。 一、已获批！这3款新药可直接用于临床 这3款新药均在2024-2026年获批，部分已进入临床，适配不同患者群体，大家可结合自身情况咨询医生。 1.度普利尤单抗（Dupixent，dupilumab）：靶点为IL-4Rα，能抑制IL-4/IL-13双通路。2024年9月FDA批准其用于慢阻肺，适用于嗜酸性粒细胞≥300 cells/µL、标准治疗控制不佳的成人患者，中国也在2024年批准了这一适应症，目前临床已可使用。 2.恩塞芬汀（Ohtuvayre，ensifentrine）：靶点为PDE3/PDE4双重抑制，2024年6月FDA获批，是20余年来首款全新作用机制的吸入式慢阻肺维持治疗药物，兼具支气管扩张与非甾体抗炎作用，通过标准喷雾器给药。中国香港2026年3月获批，澳门2025年2月、海南博鳌2024年11月已可及，中国于2026年1月受理申请，获批在即。 3.美泊利珠单抗（Nucala，mepolizumab）：靶点为IL-5，可减少嗜酸性粒细胞，2025年5月FDA批准，适用于嗜酸性粒细胞≥150 cells/µL的成人患者，是目前唯一在该低阈值进行大规模评估的生物制剂。中国于2026年1月批准，为国内首个每月一次的慢阻肺生物制剂，仅供皮下注射，剂量100mg，每4周一次。 二、2026重点在研药：未来治疗新方向 这两款候选药处于研发关键阶段，有望为更多患者带来新选择，值得持续关注。 1.Tozorakimab（阿斯利康）：靶点为IL-33，双通路抑制，与同类药物机制不同。目前有四项3期试验正在开展，均为皮下注射给药。最新进展显示，其OBERON和TITANIA两项3期试验已达到主要终点，PROSPERO扩展研究预计2026年6月完成，整体研究预计8月完成。2期试验中，虽未达到整体主要终点，但高急性加重风险亚组显示出阳性疗效信号。 2. 特泽利尤单抗（Tezepelumab阿斯利康/安进）：靶点为上游炎症因子TSLP，目前处于2a期阶段，试验整体未达统计显著性，但在BEC≥150 cells/µL亚组中，急性加重率下降37%，BEC≥300亚组下降46%，目前企业正积极规划3期试验。 该药哮喘与慢性鼻窦炎伴鼻息肉适应症在国内已获批上市，详情：重磅！哮喘和鼻息肉双适应症TSLP新药，特泽利尤单抗（泰适卓）中国获批 三、相邻领域突破：提供新思路 Brinsupri（brensocatib）：靶点为DPP1抑制剂，2025年8月12日FDA批准其用于非囊性纤维化支气管扩张症，是全球首个上市的DPP1抑制剂，每日口服一次。虽适应症并非慢阻肺，但其作用靶点相关通路，对中性粒细胞型慢阻肺有潜在适用性，当年阿斯利康保留了其慢阻肺适应症，后续值得关注。 关于这些新药，你有什么疑问或使用顾虑，欢迎在评论区留言交流～ 新药临床分享 慢阻肺、哮喘新药（上文同原理）临床试验正在招募受试者，如TSLP 和 IL-13双靶点/达必妥同靶点/礼来Lebrikizumab来瑞组单抗/特泽利尤单抗同靶点/美泊利珠单抗同靶点。 临床均在三甲医院开展，专家随访，符合条件的患者体检用药均不收费。 新药临床 直接报名 客服微信 进患者群 【清霏岩盐气溶胶治疗仪】非药物物理疗法，化痰祛痰、抗炎消肿，提升呼吸免疫力。现推出3次免费试用（押金模式），效果满意再付款，不满意全额退款！适用于鼻炎、哮喘、慢阻肺。添加客服微信，立即参与体验！ 参考文献： 1. FDA官网：Dupixent、Ohtuvayre、Nucala、Brinsupri获批公告 2. NMPA官网：度普利尤单抗、美泊利珠单抗慢阻肺适应症获批信息 3. 21世纪经济报道：《赛诺菲特药中国区总经理纪娴:再拓免疫版图，共筑2型炎症诊疗生态》 4. 经济参考报：《晶泰科技旗下Ailux任命前阿斯利康高管为首席科学官》 5. 全国党媒信息公共平台：《近期中美欧批准上市新药盘点》 往 期 回 顾 慢阻肺全再乐（氟替美维）使用全攻略：操作步骤/注意事项/咽喉副作用对比 慢阻肺什么情况该打美泊利珠等生物制剂？未来有哪些新药研究方向？ 本文仅做参考，不构成对任何药物或诊疗方案的推荐、推广或宣传，也不可替代专业医疗建议。如有问题，请咨询医疗卫生专业人士。材料图片等源自网络，侵删。 点分享 点收藏 点在看 点点赞

→ A decorated GLP-1 pioneer is retiring at Novo Nordisk . Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on LinkedIn that she “has left the building” after 36 years with Novo. Knudsen won the Breakthrough Prize last year with Jens Juul Holst of the Novo Nordisk Foundation Center for Basic Metabolic Research, along with three other scientists, for discovering the peptide that has rocked the industry. She created liraglutide , which is sold as Saxenda for weight loss and Victoza for type 2 diabetes. And while Eli Lilly means business as Novo’s fiercest competitor in the obesity space — adding another approval last week with its GLP-1 pill Foundayo — Ozempic and Wegovy have become household names as Knudsen’s long career draws to a close. “To have played such a pivotal role in advancing science that has meant so much to so many people —that is a privilege beyond measure,” Knudsen wrote. → As it readies itself to release crucial Phase 3 data on its weight loss candidate, Boehringer Ingelheim has lured an obesity specialist away from Novo Nordisk. According to a LinkedIn post , Sylvia Shubert has joined the German drugmaker as SVP of obesity and liver health. She will have much to do in her new role: The American Diabetes Association’s annual meeting in June will see the presentation of data from two late-stage trials of survodutide , the GLP-1 and glucagon agonist that grew out of a 2011 metabolic drug development collaboration between Boehringer and Zealand Pharma . If the data are positive, the company will want to gear up for the shot’s launch in the increasingly competitive obesity space. Before moving to Boehringer, Shubert spent nearly two years at Novo as VP and US therapeutic area head for obesity. She helped oversee the sale of Wegovy, including its launch in new uses — for reducing the risk of cardiovascular events and treating the fatty liver disease MASH. Her experience might come in handy at Boehringer, since survodutide is also in late-stage MASH trials. Earlier, Shubert spent three and a half years at J&J and nearly 14 years at Novartis . → Roche ’s radiotherapy partner Orano Med has tapped Frederic Desdouits as CEO. The Pierre Fabre alum was on the board of directors at TreeFrog Therapeutics before he became CEO of the French stem cell biotech in 2021. Mark Rothera , the former CEO of Orchard Therapeutics , Silence Therapeutics and Viracta Therapeutics , replaced Desdouits at TreeFrog in December. Orano Med also partnered with Sanofi for their radiopharmaceutical AlphaMedix in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Despite encouraging data , Sanofi disclosed in its Q4 update that it deprioritized the asset, opening the door for Perspective Therapeutics to potentially compete with Novartis’ Lutathera . → Dutch ADC developer Byondis has promoted Christoph Korpus to replace Jacques Lemmens as CEO. Lemmens will still chair the board of the company he founded. The new chief executive wrapped up an eight-year tenure with Merck KGaA in December 2024 and became CBO at Byondis in January 2025. Korpus was elevated to director, global business development and licensing oncology at Merck KGaA, a job title he kept for his last three years at the German pharma. → BioCryst has plucked Sandeep Menon from Alnylam and he will lead R&D at the Orladeyo maker, which snapped up another hereditary angioedema candidate when it bought Astria Therapeutics last fall. Menon was chief development officer, head of clinical development and safety for Alnylam, playing a pivotal role in the approval of its heart drug Amvuttra . He held multiple positions over a 13-year career with Pfizer , including CSO, BioMedicine AI and digital sciences. Jon Stonehouse retired from BioCryst on Dec. 31 and handed the reins to commercial chief Charlie Gayer . → Days after Endpoints News exclusively revealed Phase 1b data for Enveda ’s eczema candidate ENV-294 , CEO Viswa Colluru wrote on LinkedIn that Inhwan Kim has been promoted to chief strategy officer. Kim spent the last 18 months as SVP, portfolio strategy & operations. “Three years ago, I came across Enveda in a random late-night LinkedIn post and found its core thesis — to discover novel medicines from life’s chemistry, refined for biological relevance over billions of years of natural R&D — so compelling that I applied on the spot, hoping to be part of the story,” Kim wrote in a separate LinkedIn post . Three years later, Colluru said the new position “formalizes what’s already been true: Inhwan is one of the people who decides what Enveda becomes.” → Peter Anastasiou has been called up from the board of directors to take the COO job at Harmony Biosciences , while Rapport Therapeutics CFO Troy Ignelzi and ex- Sage chairman Geno Germano each nab a spot on the board. Anastasiou has been a board member at Harmony since 2023 and ran Capsida Biotherapeutics from 2022-25 following a 12-year run at Lundbeck . In September, Capsida said a patient died in a trial that was evaluating its gene therapy for a rare brain disorder, and Anastasiou’s LinkedIn page indicates that he left the company a month later. The biotech later revealed in an open letter that the patient died from cerebral edema. Former Acelyrin chief Mina Kim is still listed as interim CEO on Capsida’s website. Harmony also said that Valor Equity Partners ’ Antonio Gracias will step down from the board. → Overcoming a CRL to finally win the first-ever FDA approval for a Barth syndrome treatment, Stealth BioTherapeutics has promoted David Brown to CSO. Few people know the company as well as Brown, who advised Stealth for seven years before joining the team as senior director, scientific and technical innovation in 2019. He moves up to the CSO slot after two years as SVP of discovery. “I am energized by the work we do at Stealth every day to translate deep knowledge of mitochondrial bioenergetics into new medicines for people facing debilitating diseases,” Brown said in a press release . → Norwegian I/O player Lytix Biopharma has selected Novo Nordisk alum Renée Christine Amundsen as COO. Amundsen left Novo last year and was corporate VP for the diabetes commercial unit. Lytix is studying an oncolytic molecule called ruxotemitide as a monotherapy and in combination with Merck ’s Keytruda . → Tenpoint Therapeutics reached the regulatory checkered flag in January with an FDA approval for its presbyopia eye drop Yuvezzi . This week, Tenpoint has welcomed Stephen Lane as CMO. Lane held this position at eye care specialist Alcon , where he was also head of medical safety. When the approval came through, Tenpoint said it hauled in a combined $235 million from an $85 million Series B and a $150 million debt facility. → Joti Marango has landed at Gaithersburg, MD-based Remedy Plan Therapeutics as chief financial and business officer. The former Aptose exec had juggled the roles of COO and CFO at Ikena Oncology , which reverse merged with Inmagene and rebranded to ImageneBio under the ticker $IMA . “With our first oncology study now underway, our differentiated approach to NAMPT inhibition positions us well to tackle increasingly broader segments of the oncology market,” Marango said in a statement . → TuHURA Biosciences , which did a reverse merger of its own with Kintara , has brought in Amanda Garofalo as SVP of clinical operations. The EMD Serono vet also led clinical operations at Parabilis Medicines , a cancer biotech co-founded by Greg Verdine that was once known as FogPharma . After the Kintara agreement, TuHURA then merged with Kineta and picked up a VISTA-inhibiting monoclonal antibody that’s now codenamed TBS-2025 . → Palvella Therapeutics is back for the second time in the last three editions of Peer Review, hiring Kent Taylor as SVP of sales. Taylor had the same responsibilities at Arcutis Biotherapeutics and was VP of sales, dermatology for the inflammation & autoimmunity group at Incyte . We told you that Jennifer McDonough jumped to Palvella last month as SVP of market access and patient services. → Mineralys Therapeutics CEO Jon Congleton has punched his ticket to the board of directors at Avalyn Pharma , the pulmonary fibrosis specialist that filed its S-1 paperwork this week. It’s his second appointment in as many weeks after joining the board at Immunic . → Stoke Therapeutics has added Pfizer veteran Clare Kahn to its board of directors. Kahn has spent the last five years on the board at Solid Biosciences , where Stoke CEO Ian Smith is chairman. Stoke and Biogen are currently testing a Dravet syndrome drug called zorevunersen in a Phase 3 study. → The non-opioid pain experts at Latigo Biotherapeutics have elected Insmed CFO Sara Bonstein to the board of directors. Insmed had a rough go of it this week as the prospects of a label expansion for Brinsupri continue to dim . Meanwhile, Latigo is hoping its Nav1.8 inhibitor can set up a showdown with Vertex ’s Journavx . → Cleveland, OH-based cell and gene therapy maker Abeona Therapeutics has made room for Syndax Pharmaceuticals CFO Keith Goldan on the board of directors. Goldan held the CFO post at Optinose from 2017-22.